Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial

E Capelletto, MR Migliorino, A Morabito, R Chiari, F Grossi, M Tiseo, FD Costanzo, A Delmonte, G Romano, D Galetta, V Scotti, V Gregorc, S Pisconti, GL Ceresoli, AD Conte, L Ciuffreda, I Colantonio, E Bria, S Ricciardi, A ManzoG Metro, AM Morelli, R Critelli, MV Pacchiana, I Stura, G Migliaretti, S Novello

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: Despite the scant docetaxel's tolerability, second-line association with nintedanib still represents a standard-of-care for non-squamous non-small cell lung cancer (nsNSCLC), giving to rapidly-progressing patients the greatest survival advantage. The SENECA trial is a phase IIb, open-label, study evaluating whether nintedanib/docetaxel can be equally effective and safe regardless docetaxel schedule. Materials and Methods: Recurrent nsNSCLC patients were stratified into cohort 1 and 2, according to relapse-time (within or over 3 months) from end of first-line chemotherapy. They were treated with docetaxel (T1: 33 mg/mq on days 1 and 8 in a 21-days cycle; T2: 75 mg/mq q3wks) plus nintedanib, allowing maintenance in case of disease-control. Primary endpoint was progression-free survival (PFS) by investigator's assessment; secondary endpoints: overall survival (OS), safety and quality-of-life. Results: Between January 2016-April 2018, 212 patients were evaluated: 30 resulted screening-failures, 12 were excluded for lack of compliance. According to investigator's choice, 85 patients received T1 docetaxel and 85 T2; 138 (81.2%) were stratified in C1, 32 (18.8%) in C2, with a median relapse-time of 0.54 and 9.29 months, respectively. Baseline characteristics were balanced between groups. After 35.5 months follow-up, no survival differences appear between cohorts and treatments; toxicity seems to be slightly higher in T2, especially for chemotherapy-related events. Perception of quality-of-life remains stable and docetaxel schedule doesn't modify patients’ load. Conclusion: The SENECA trial confirms efficacy of second-line nintedanib/docetaxel for nsNSCLC, regardless time of recurrence and docetaxel schedule; higher toxicities for q3wks docetaxel, without alterations in quality-of-life, have been described, underling the possibility, adopting the weekly schedule, to maintain efficacy with better tolerability. © 2019 Elsevier B.V.
Original languageEnglish
Pages (from-to)210-217
Number of pages8
JournalLung Cancer
Volume134
DOIs
Publication statusPublished - 2019

Fingerprint Dive into the research topics of 'Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial'. Together they form a unique fingerprint.

Cite this